Shares of Compugen ( CGEN) climbed Tuesday on news the company had inked a deal to collaborate with Teva Pharmaceutical ( TEVA) on a project to discover biomarkers that can indicate drug toxicity prior to clinical stages of drug development.

The two Israel-based companies will focus initially on biomarkers for the early detection of potential nephrotoxicity, or toxicity of the kidney cells.

Under the terms of the agreement, Teva gets a license to use the discovered markers for research-and-development activities, and Compugen retains commercialization rights for licensing to other companies, as well as rights for internal use.

Shares of small-cap Compugen were up 21 cents, or 7.4%, at $3.06 in recent trading Tuesday. Teva shares were down 4 cents, or 0.1%, at $34.72.

More from Stocks

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Facebook CEO Mark Zuckerberg Deflects Tough Questions From European Parliament

Facebook CEO Mark Zuckerberg Deflects Tough Questions From European Parliament